388 results
DEFA14A
IMGN
Immunogen, Inc.
29 Jan 24
Additional proxy soliciting materials
5:01pm
opportunities or strategic transactions; risks associated with litigation relating to the Merger; risk that shareholder litigation may result in significant
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
ImmunoGen’s ability to pursue certain business opportunities or strategic transactions; risks associated with litigation relating to the Merger; risk … that shareholder litigation may result in significant costs of defense, indemnification and liability; the possibility that competing offers may be made
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
, or the Proxy Statement (such letters, the “Demands” and, collectively with the Merger Actions, the “Litigation Matters”).
ImmunoGen believes … that the claims asserted in the Litigation Matters are without merit and that no further disclosure beyond that already contained in the Proxy Statement
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
, the “Litigation Matters”).
ImmunoGen believes that the claims asserted in the Litigation Matters are without merit and that no further disclosure beyond … that already contained in the Proxy Statement is required under applicable law to supplement the Proxy Statement, as claimed in the Litigation Matters
DEFA14A
IMGN
Immunogen, Inc.
8 Jan 24
Additional proxy soliciting materials
4:12pm
transactions; risks associated with litigation relating to the Merger; risk that shareholder litigation may result in significant costs of defense
8-K
g07pc
8 Jan 24
Other Events
4:11pm
DEFM14A
q1oxl
2 Jan 24
Proxy related to merger
4:26pm
PREM14A
zsgw2c9
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
meegih6n69c4z fy0htr
21 Dec 23
Additional proxy soliciting materials
3:54pm
DEFA14A
liroprgo6m171z5h5
30 Nov 23
Additional proxy soliciting materials
4:08pm
DEFA14A
EX-2.1
84wm709
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-99.1
3ybud tfejoo
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
d9j0go 5yew
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
8tqzmm6hqc2odap
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
f2u 6gnc9vqcdx
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
z8zir6ip3cog5o
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-1.1
b3y0aac9o3im5dfechfg
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
2s421ib6 5augth77zh
5 May 23
Prospectus supplement for primary offering
4:49pm